Delaying a treatment switch in antiretroviral-treated HIV type 1-infected patients with detectable drug-resistant viremia does not have a profound effect on immune parameters: AIDS Clinical Trials Group Study A5115.

Delaying a treatment switch in antiretroviral-treated HIV type 1-infected patients with detectable drug-resistant viremia does not have a profound effect on immune parameters: AIDS Clinical Trials Group Study A5115. AIDS Res Hum Retroviruses. 2009 Feb; 25(2):135-9.

View in: PubMed

subject areas

Acquired Immunodeficiency Syndrome
Anti-Retroviral Agents
Antiretroviral Therapy, Highly Active
Candida
CD4 Lymphocyte Count
Cell Proliferation
Drug Resistance, Viral
HIV-1
Humans
Mycobacterium avium Complex
RNA, Viral
Viral Load

authors with profiles

Alan L. Landay